Education
About Us
Working with TipRanks
Follow Us
Alkermes (ALKS)
NASDAQ:ALKS
ALKS Stock Chart & Stats
$28.50
-$0.20(-0.70%)
At close: 4:00 PM EST
$28.50
-$0.20(-0.70%)
Day’s Range― - ―
52-Week Range$25.17 - $36.45
Previous CloseN/A
Volume176.14K
Average Volume (3M)2.46M
Market Cap
$4.82B
Enterprise Value$4.02B
Total Cash (Recent Filing)$1.11B
Total Debt (Recent Filing)$71.60M
Price to Earnings (P/E)14.1
Beta0.69
Next Earnings
Feb 12, 2026EPS Estimate
0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.68
Shares Outstanding165,117,510
10 Day Avg. Volume1,671,328
30 Day Avg. Volume2,456,900
Financial Highlights & Ratios
PEG Ratio3.47
Price to Book (P/B)3.25
Price to Sales (P/S)3.05
P/FCF Ratio11.73
Enterprise Value/Market Cap0.83
Enterprise Value/Revenue2.64
Enterprise Value/Gross Profit3.07
Enterprise Value/Ebitda9.22
Forecast
1Y Price Target
$46.17Price Target Upside62.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)1.69
Revenue Forecast (FY)$1.47B
Bulls Say, Bears Say
Bulls Say
Acquisition StrategyAlkermes' acquisition of Avadel adds Lumryz, a growing drug for NT1 & 2, which should be immediately accretive upon deal close and add over $275 million to topline.
Clinical AdvancementsAlkermes reported positive topline data from the Vibrance-2 Phase 2 study of alixorexton in Narcolepsy Type 2 (NT2), positioning it as the first oral orexin 2 receptor agonist to demonstrate efficacy in a randomized Ph2 study in NT2.
Market PositionAlkermes now appears positioned to be first-to-market with an orexin-2 in both NT1 and NT2, which offers commercial value.
Bears Say
Clinical Data LimitationsThe data disclosed for alixorexton in NT2 patients was limited, and further clarity is needed.
Efficacy ComparisonsALKS was under pressure following release of VIBRANCE-2 data on concerns that alixorexton looked less efficacious than ORX-750.
Market Impact ConcernsThere is some controversy among sleep specialists about the utility of Lumryz in IH patients, affecting its potential market impact.
Alkermes News
ALKS FAQ
What was Alkermes’s price range in the past 12 months?
Alkermes lowest stock price was $25.16 and its highest was $36.45 in the past 12 months.
What is Alkermes’s market cap?
Alkermes’s market cap is $4.82B.
When is Alkermes’s upcoming earnings report date?
Alkermes’s upcoming earnings report date is Feb 12, 2026 which is in 60 days.
How were Alkermes’s earnings last quarter?
Alkermes released its earnings results on Oct 28, 2025. The company reported $0.684 earnings per share for the quarter, beating the consensus estimate of $0.369 by $0.315.
Is Alkermes overvalued?
According to Wall Street analysts Alkermes’s price is currently Undervalued.
Does Alkermes pay dividends?
Alkermes does not currently pay dividends.
What is Alkermes’s EPS estimate?
Alkermes’s EPS estimate is 0.42.
How many shares outstanding does Alkermes have?
Alkermes has 165,117,510 shares outstanding.
What happened to Alkermes’s price movement after its last earnings report?
Alkermes reported an EPS of $0.684 in its last earnings report, beating expectations of $0.369. Following the earnings report the stock price went up 4.307%.
Which hedge fund is a major shareholder of Alkermes?
Currently, no hedge funds are holding shares in ALKS
Alkermes Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$46.17 (62.00% Upside)
$46.17 (62.00% Upside)
Blogger Sentiment
Bullish
ALKS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 886.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.0%
Last 30 Days ▲ 7.6%
Last 30 Days ▲ 7.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.55%
12-Months-Change
Fundamentals
Return on Equity
22.35%
Trailing 12-Months
Asset Growth
8.08%
Trailing 12-Months
Company Description
Alkermes
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
ALKS Company Deck
ALKS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call indicates a strong performance in Q3 2025, with significant revenue growth and raised financial guidance for the year. The acquisition of Avadel Pharmaceuticals is positioned as a strategic move to enhance Alkermes' portfolio and market position. While there are concerns over increased R&D and SG&A expenses, the overall outlook remains positive with promising advancements in the orexin 2 receptor agonist portfolio.View all ALKS earnings summariesALKS Revenue Breakdown
89.69% U.S.
10.24% Rest of world
0.07% Ireland
ALKS Stock 12 Month Forecast
Average Price Target
$46.17
▲(62.00% Upside)
Technical Analysis
Ownership Overview
1.40% Insiders
29.56% Mutual Funds
25.70% Other Institutional Investors
12.43% Public Companies and
Individual Investors